ArticleBMC plant biology2026
Mitigating grapevine esca disease: an innovative integrated management strategy to reduce incidence and severity by enhancing plant physiology and defence mechanisms.
Article in BMC plant biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Esca is one of the most destructive grapevine trunk diseases and a growing challenge for viticulture worldwide, particularly in the context of climate-driven increases in disease expression. Due to the lack of curative solutions and the limited efficacy of currently available preventive measures, there is a pressing need for sustainable, field-ready strategies capable of mitigating disease impact. In this study, we assessed the performance of AF5, a novel foliar formulation composed of potassium acetate, α-tocopherol, and propylenic glycol, applied throughout the growing season. Field trials were conducted over three consecutive years in three vineyards located in distinct pedoclimatic areas of northern Italy. Across all sites and seasons, AF5 consistently reduced esca incidence and severity, with decreases ranging from 26 to 40% and 35% to 50%, respectively, compared with the conventional management protocol adopted by each winery. To investigate the physiological basis of this mitigation, we measured leaf-level gas exchange in symptomatic and asymptomatic vines. AF5-treated symptomatic plants displayed higher stomatal conductance and transpiration than untreated symptomatic vines, indicating a partial alleviation of the hydraulic limitations typically associated with esca-induced xylem dysfunction. To complement these observations, RNA sequencing of leaf tissues revealed a clear transcriptional activation of defence-related pathways in AF5-treated symptomatic vines. Genes involved in pathogen perception (e.g., receptor-like kinases), ethylene and jasmonate signalling cascades, and immune-regulatory transcription factors such as WRKYs and FRK1 were strongly induced, suggesting that AF5 enhances host defensive preparedness. Overall, this study provides the first multi-year, multi-site evidence that AF5 can reduce disease expression while supporting physiological performance and activating key immune pathways. These results position AF5 as a promising, easily implementable tool for integrated esca management in commercial vineyards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.